会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 57. 发明授权
    • Apparatus of fabricating and method of fabricating liquid ejection head, and liquid ejection head
    • 制造液体喷射头的制造方法和液体喷射头
    • US07669329B2
    • 2010-03-02
    • US12053470
    • 2008-03-21
    • Hideyuki OgawaKoichi SaitoNagamitsu TakashimaKatsumi MotojimaKatsunori Ono
    • Hideyuki OgawaKoichi SaitoNagamitsu TakashimaKatsumi MotojimaKatsunori Ono
    • B23P17/00
    • B41J2/1632B41J2/162Y10T29/49401Y10T29/49826
    • A method of fabricating a liquid ejection head is provided. The method includes preparing a first die including projected streak portions aligned in parallel by a predetermined pitch and gap portions formed between the adjacent projected streak portions. The first die is adapted to form groove-like recess portions by pressing the projected streak portions to a metal plate. The method further includes preparing a second die for supporting the metal plate to which the projected streak portions of the first die are pressed. Each of the projected streak portions includes: an inner wall forming portion for forming an inner wall of the corresponding groove-like recess portion extending in a depth direction of the corresponding groove-like recess portion; a connecting face portion; and an inclined face portion, continuous via the connecting face portion to the inner wall forming portion, for forming a bottom portion of the corresponding groove-like recess portion into a substantially V-like shape.
    • 提供一种制造液体喷射头的方法。 该方法包括制备包括以预定间距平行排列的突出条纹部分和形成在相邻突出条纹部分之间的间隙部分的第一裸片。 第一模具适于通过将突出的条纹部分压入金属板而形成凹槽状的凹部。 该方法还包括制备用于支撑金属板的第二模具,第一模具的突出条纹部分被按压到该金属板。 每个突出部分包括:内壁形成部分,用于形成在相应的槽状凹部的深度方向上延伸的相应的槽状凹部的内壁; 连接面部; 以及经由连接面部连接到内壁形成部的倾斜面部,用于将相应的槽状凹部的底部形成为大致V字状。
    • 58. 发明授权
    • Artificial cell comprising mutant estrogen receptor
    • 包含突变体雌激素受体的人造细胞
    • US07582476B2
    • 2009-09-01
    • US10148835
    • 2000-12-01
    • Koichi SaitoNorihisa OheHideo Satoh
    • Koichi SaitoNorihisa OheHideo Satoh
    • C12N5/10C12N15/11
    • C07K14/721
    • The present invention provides in general an artificial cell, an isolated mutant ERα, an isolated polynucleotide encoding the mutant ERα, a method for quantitatively analyzing an activity for transactivation of a reporter gene by a test ERα, a method for screening a mutant ligand dependent transcriptional factor, a method for evaluating an activity for transactivation of a reporter gene by a test ERα, a method for screening a compound useful for treating a disorder of a mutant ERα, a pharmaceutical agent useful for treating an estrogenic disorder of a mutant ERα, use of the mutant ERα, a method for diagnosing a genotype of a polynucleotide encoding a test ERα, a method for diagnosing a genotype of a polynucleotide encoding a test ERα and a method for diagnosing a phenotype of a test ERα.
    • 本发明一般提供人造细胞,分离的突变体ERα,分离的编码突变体ERα的多核苷酸,通过测试ERalpha定量分析报告基因的反式活化的活性的方法,筛选突变配体依赖性转录的方法 因子,通过测试ERalpha评估报告基因的反式活化的活性的方法,用于筛选用于治疗突变型ERalpha病症的化合物的方法,用于治疗突变型ERalpha的雌激素病症的药物,使用 的突变体ERalpha,用于诊断编码测试ERalpha的多核苷酸的基因型的方法,用于诊断编码测试ERalpha的多核苷酸的基因型的方法和用于诊断测试ERalpha的表型的方法。
    • 59. 发明申请
    • EMULSIFIED COMPOSITION FOR DILUTION AND CANCER VACCINE COMPOSITION
    • 用于稀释和癌症疫苗组合物的乳化组合物
    • US20090136572A1
    • 2009-05-28
    • US11814270
    • 2006-01-19
    • Koichi SaitoYusuke Okawa
    • Koichi SaitoYusuke Okawa
    • A61K9/14A61K39/00A61K47/00
    • C07K7/08A61K9/0019A61K9/107A61K39/0011A61K47/14A61K2039/55566C07K7/06
    • Provided is an emulsified composition for diluting a cancer antigen peptide or a dimer thereof. Also provided is a novel cancer vaccine composition or specific CTL inducer that efficiently induces CTL irrespective of the type of cancer antigen peptide when mixing the emulsified composition for dilution and a water phase comprising a cancer antigen peptide or a dimer thereof.The present invention relates to an emulsified composition for diluting a cancer antigen peptide or a dimer thereof, comprising a particular ester, a particular surfactant, a particular emulsifier, and a water phase. The present invention also relates to a cancer vaccine composition or specific CTL inducer obtained by freshly diluting and mixing a water phase comprising a cancer antigen peptide or a dimer thereof with the emulsified composition for dilution.
    • 提供了用于稀释癌抗原肽或其二聚体的乳化组合物。 还提供了当混合用于稀释的乳化组合物和包含癌抗原肽或其二聚体的水相时,与癌抗原肽类型无关地有效诱导CTL的新型癌症疫苗组合物或特异性CTL诱导剂。 本发明涉及用于稀释癌抗原肽或其二聚体的乳化组合物,其包含特定的酯,特定的表面活性剂,特定的乳化剂和水相。 本发明还涉及通过将包含癌抗原肽或其二聚体的水相与用于稀释的乳化组合物新鲜稀释和混合而获得的癌症疫苗组合物或特异性CTL诱导剂。